Welcome to our dedicated page for Cerus SEC filings (Ticker: CERS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cerus Corporation filings document financial and governance disclosures for a biomedical products company focused on transfusion safety. Recent 8-K reports furnish operating results, preliminary product revenue, revenue guidance, and business updates tied to the INTERCEPT Blood System, INTERCEPT Fibrinogen Complex, government contract revenue, product margins, and related pipeline activity.
The company’s proxy and material-event filings also cover annual meeting matters, board composition, executive compensation, severance arrangements, compensatory plans, and officer or director changes. These filings provide formal records of Cerus’ public-company governance, Nasdaq-listed common stock reporting, capital-structure disclosures, and material events connected to its blood-safety product business.
Cerus Corporation (CERS) reported its third-quarter 2025 results for the period ended September 30, 2025. The company furnished a press release titled “Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance” as Exhibit 99.1.
The information was furnished under Item 2.02 and is not deemed filed for liability purposes. An Inline XBRL cover page was included as Exhibit 104.
CERUS CORP reporting person Dean A. Gregory (Director) effected a purchase of 25,000 shares of Cerus common stock on 08/25/2025 at a price of $1.25 per share. After the transaction the reporting person beneficially owned 86,725 shares. The Form 4 was filed by one reporting person and executed by an attorney-in-fact, Chrystal N. Jensen.
Baker Bros. Advisors and related persons disclosed ownership stakes in Cerus Corporation (CERS) in Amendment No. 11 to a Schedule 13G/A. The filing reports that two Baker Brothers funds (667, L.P. and Baker Brothers Life Sciences, L.P.) beneficially own a combined 12,883,844 shares, representing 6.7% of Cerus based on 191,160,480 shares outstanding as of April 17, 2025. The cover pages show Julian C. Baker and Felix J. Baker each with beneficial ownership of 12,903,708 shares (6.8%), which reflects their direct holdings including 19,864 in-kind distributed shares. The filing states the Adviser has sole voting and dispositive power over the funds' shares. The amendment is signed and dated 08/14/2025.
Cerus Corporation (CERS) filed a Form 8-K to announce a governance change effective June 16, 2025. Long-standing board chair Daniel N. Swisher, Jr. retired from the board and its committees with no reported disagreements over company matters. To maintain continuity, the board moved quickly on June 20 to promote CEO William M. Greenman to chair while appointing Frank Witney, Ph.D. as lead independent director. Both directors will serve in their existing board classes, expiring at the 2026 and 2027 annual meetings, respectively. No other operational or financial data were disclosed in the filing.
The change consolidates the CEO and chair roles, offset by the creation of a lead independent director position intended to preserve board oversight. Investors should view the update as a routine succession matter with limited immediate financial impact but modest corporate-governance implications.